Influence of the Journal of Nuclear Medicine jumps 25%

June 27, 2019

The Journal of Nuclear Medicine (JNM)--the flagship publication of the Society of Nuclear Medicine and Molecular Imaging (SNMMI)--has again been ranked among the top medical imaging journals worldwide, according to new data just released in the 2018 Journal Citation Reports© published by Clarivate Analytics.

The Journal Citation Report publishes an immediacy index for journals as an indicator of the speed with which citations to a specific journal appear in published literature. JNM's immediacy index for 2018 is 3.094, a 25% increase over last year and almost double the index of the previous year.

JNM's 2018 impact factor was 7.354, with a five-year impact factor of 6.738. The journal's citations increased from 27,101 to 27,551, and its article influence score increased from 1.852 to 1.876. JNM ranked fifth of the 129 journals included in the medical imaging category? the highest rank among all nuclear medicine journals?with the European Journal of Nuclear Medicine and Molecular Imaging close behind.

"The dramatic increase in JNM's immediacy index over the past two years demonstrates the journal's influential role in molecular imaging, and we are honored that it is the journal of choice for many distinguished researchers," said Editor-in-Chief Johannes Czernin, MD, professor of molecular and medical pharmacology and chief of the Ahmanson Translational Imaging Division at the UCLA David Geffen School of Medicine, Los Angeles, California. "Among nuclear medicine journals, JNM continues to have the highest number of citations, the highest average 5-year impact factor, the highest number of citable articles, and the highest influence score."
-end-
The Institute for Scientific Information (ISI), now based in Clarivate Analytics' Scientific and Academic Research Group, measures a journal's impact--or significance--based on the number of article citations compared to the total number of articles published in the previous two years. The impact factor--a quantitative measure of the frequency with which an article in a journal is cited--is used to gauge the overall influence of a journal within scientific, professional and academic communities. For more than 50 years, ISI has provided a systematic and objective way for librarians, researchers and other decision-makers to measure influence in the global research community.

The Journal of Nuclear Medicine is available online at JNM.snmjournals.org">http://JNM.snmjournals.org. To subscribe, visit http://www.snmmi.org/Subscribe. To order a copy, contact the SNMMI Subscription Services at subscriptions@snmmi.org or telephone 1-800-513-6853.

About the Society of Nuclear Medicine and Molecular Imaging

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging, vital elements of precision medicine that allow diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.

SNMMI's more than 16,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit http://www.snmmi.org.

Society of Nuclear Medicine and Molecular Imaging

Related Molecular Imaging Articles from Brightsurf:

New technique offers higher resolution molecular imaging and analysis
The new approach from Northwestern Engineering could help researchers understand more complicated biomolecular interactions and characterize cells and diseases at the single-molecule level.

Molecular imaging offers insight into therapy outcomes for neuroendocrine tumor patients
A new proof-of-concept study published in the May issue of The Journal of Nuclear Medicine has demonstrated that molecular imaging can be used for identifying early response to 177Lu-DOTATATE treatment in neuroendocrine tumor patients.

Non-invasive imaging method spots cancer at the molecular level
Researchers for the first time have combined a powerful microscopy technique with automated image analysis algorithms to distinguish between healthy and metastatic cancerous tissue without relying on invasive biopsies or the use of a contrast dye.

Molecular imaging suggests smokers may have impaired neuroimmune function
Research presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNM MI) shows preliminary evidence that tobacco smokers may have reduced neuroimmune function compared with nonsmokers.

Novel noninvasive molecular imaging for monitoring rheumatoid arthritis
A first-in-human Phase 1/Phase II study demonstrates that intravenous administration of the radiopharmaceutical imaging agent technetium-99m (99mTc) tilmanocept promises to be a safe, well-tolerated, noninvasive means of monitoring rheumatoid arthritis disease activity.

Improving molecular imaging using a deep learning approach
Generating comprehensive molecular images of organs and tumors in living organisms can be performed at ultra-fast speed using a new deep learning approach to image reconstruction developed by researchers at Rensselaer Polytechnic Institute.

Nanoplatform developed with three molecular imaging modalities for tumor diagnosis
Nanotechnology and biotechnology are bringing us increasingly closer to personalised cancer treatment.

Study suggests molecular imaging strategy for determining molecular classifications of NSCLC
Recent findings suggest a novel positron emission tomography (PET) imaging approach determining epidermal growth factor receptor (EGFR) mutation status for improved lung cancer patient management.

New imaging technique able to watch molecular dynamics of neurodegenerative diseases
Researchers have developed a fast and practical molecular-scale imaging technique that could let scientists view never-before-seen dynamics of biological processes involved in neurodegenerative diseases such as Alzheimer's disease and multiple sclerosis.

Combined optical and molecular imaging could guide breast-conserving surgery
Breast-conserving surgery is the primary treatment for early-stage breast cancer, but more accurate techniques are needed to assess resection margins during surgery to avoid the need for follow-up surgeries.

Read More: Molecular Imaging News and Molecular Imaging Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.